Semaglutide and tirzepatide products have different indications, dosing schedules, contraindications, warnings, and side-effect profiles
The latter one which included 4 trials (43,456 patients) suggested that GLP-1 RAs reduced MACE by 13% (HR 0.87, 95% CI 0.820.93), an effect which was consistent in both subgroups (HR 0.91, 95% CI 0.850.97 and HR 0.80, 95% CI 0.720.90 with and without metformin, respectively)
This means you can use your pre-tax dollars to cover the cost of our program, making it a more affordable option for managing your health and weight loss journey
Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al
In STEP 1 (semaglutide 2.4 mg, 1,961 participants), most weight loss occurred by weeks 30 to 40, with the curve flattening after that